LOGIN
Combined & extended alendronate with teriparatide improves BMD in women with osteoporosis
November 2014
Combined & extended alendronate with teriparatide improves BMD in women with osteoporosis
Study Type:Randomized Trial
OE Level Evidence:2
Journal Level of Evidence:N/A
Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study
J Bone Miner Res. 2014 Aug;29(8):1777-85Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
125 postmenopausal women with osteoporosis who had undergone 9 months of teriparatide monotherapy were randomized to three treatment groups. Patients were allocated to either (1) continued 9 months combined teriparatide/alendronate therapy followed by 12 months extended alendronate; (2) continued 9 months combined teriparatide/raloxifene followed by 12 months extended raloxifene, or (3) continued ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.